drugset / Trial / NCT04298008
AZD6738 Plus Durvalumab in Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.
Timeline
- Start
- 2020-06-25
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 240 mg | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |